Background—Renin–angiotensin aldosterone system (RAAS) inhibitors significantly
improve outcome in heart failure (HF) patients with reduced ejection fraction (HFREF) …

In clinical setting, congestive heart failure (CHF) and chronic kidney disease (CKD) often co-
exist in patients due to common underlying predisposing factors. An intricate equilibrium …

Background Impaired renal function is frequently observed in patients with heart failure and
reduced ejection fraction (HFrEF). The differential effect of sacubitril/valsartan and …

Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan
in patients with heart failure and reduced ejection fraction. Background: Renal function is …

Rationale & Objective Angiotensin-converting enzyme (ACE) inhibitors are beneficial in
heart failure with reduced ejection fraction (HFrEF). We sought to describe longitudinal …

Aims Impaired renal function is associated with worse clinical outcomes in patients with LV
systolic dysfunction (LVSD) and heart failure. Renin–angiotensin–aldosterone system …

Background Renin-angiotensin system inhibitors (RASI) reduce adverse cardiovascular
events in patients with heart failure (HF) with left ventricular ejection fraction (LVEF)≤ 40 …

The renin–angiotensin–aldosterone system (RAAS) allows normal kidneys to maintain a
stable function in every situation of daily life but also intervenes to help when critical …

Aims To investigate the impact of patiromer on the serum potassium level and its ability to
enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) …

The prevalence of heart failure (HF) increases worldwide. Long-term maladaptive activation
of the renin–angiotensin–aldosterone system (RAAS) contributes to pathological left …